<DOC>
	<DOCNO>NCT01191801</DOCNO>
	<brief_summary>This study compare overall survival ( OS ) treatment group patient treat vosaroxin cytarabine versus patient treat placebo cytarabine .</brief_summary>
	<brief_title>Study Vosaroxin Placebo Combination With Cytarabine Patients With First Relapsed Refractory Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Other objective study include compare follow treatment group : Complete remission ( CR ) rate Safety tolerability Combined CR rate , define CR+CRp+CRi Overall remission ( OR ) rate Event-free survival ( EFS ) Durability remission ( CR combine CR ) assess leukemia-free survival ( LFS ) Percentage patient post-treatment transplantation</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Provide sign , write informed consent Are least 18 year age Have diagnosis AML accord World Health Organization ( WHO ) classification First relapse refractory AML ( refractory initial induction therapy ) Have ECOG score 02 Have adequate liver renal function indicate certain laboratory value Are nonfertile agree use adequate method contraception 30 day last treatment Have receive 2 cycle induction therapy AML Refractory relapse within previous 3 month therapy IDAC HIDACcontaining regimen Have receive hematopoietic stem cell transplant ( HSCT ) within previous 3 month Have receive active immunosuppressive therapy graftversushost disease ( GVHD ) within 2 week study start Have severe concurrent disease , history serious disease involve heart , kidney , liver , organ system Have evidence central nervous system involvement active AML Have active malignancy ( include hematologic malignancy ) diagnose malignancy within last 12 month , except nonmelanoma skin cancer cervical intraepithelial neoplasia Have active , uncontrolled infection Are receive investigational therapy Have receive previous treatment vosaroxin Are pregnant lactate Have medical , psychological , social condition may interfere consent , study participation , followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Hematologic</keyword>
	<keyword>Hematologic disease</keyword>
	<keyword>Blood</keyword>
	<keyword>Cancer</keyword>
	<keyword>Malignancy</keyword>
	<keyword>Vosaroxin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>First Relapsed AML</keyword>
	<keyword>Refractory AML</keyword>
	<keyword>VALOR</keyword>
	<keyword>Sunesis</keyword>
	<keyword>Voreloxin</keyword>
	<keyword>SNS-595</keyword>
</DOC>